437 results on '"Cazzaniga, Marina"'
Number of results to display per page
Search Results
152. Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale.
- Author
-
Bani, Marco, Rossi, Emanuela, Cortinovis, Diego, Russo, Selena, Gallina, Francesca, Hillen, Marij A., Canova, Stefania, Cicchiello, Federica, Longarini, Raffaella, Cazzaniga, Marina Elena, Bidoli, Paolo, Valsecchi, Maria Grazia, and Strepparava, Maria Grazia
- Subjects
CANCER patients ,STATISTICAL correlation ,FACTOR analysis ,HOSPITAL wards ,RESEARCH methodology ,PATIENT-professional relations ,ONCOLOGISTS ,PATIENT satisfaction ,PSYCHOMETRICS ,QUESTIONNAIRES ,RESEARCH evaluation ,RESEARCH funding ,STATISTICS ,TRUST ,DATA analysis ,STATISTICAL reliability ,VISUAL analog scale ,MULTITRAIT multimethod techniques ,RESEARCH methodology evaluation ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Introduction: The Trust in Oncologist Scale (TiOS) is an 18‐item questionnaire aimed to assess the cancer patients' trust in their oncologist and has been validated in Dutch and English language. This study aims to validate the Italian version of the TiOS (IT‐TiOS) and the TiOS‐Short Form (IT‐TiOS‐SF). Methods: The IT‐TiOS was administered to 194 patients recruited in an Italian oncology department from April to December 2018. Data collected included socio‐demographic data, health and clinical information, satisfaction with the most recent oncology visit and trust in the regional healthcare system. Internal consistency, test–retest reliability, convergent and the structural validity of both the full and short form were tested. Results: Factor analyses indicated that neither four‐factor nor one‐factor models of the full scale were acceptable. However, confirmatory factor analysis supported the one‐dimensionality of the IT‐TiOS‐SF, and internal consistency assessed with Cronbach's alpha was 0.88. Mean scores on the IT‐TiOS‐SF correlated with satisfaction with the oncologist (rs = 0.64) and willingness to recommend the oncologist to others (rs = 0.67), confirming good construct validity. Conclusion: The IT‐TiOS‐SF demonstrates good psychometric properties and can be used to assess trust for both clinical and research purposes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
153. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
- Author
-
O'Shaughnessy, Joyce, Brezden-Masley, Christine, Cazzaniga, Marina, Dalvi, Tapashi, Walker, Graham, Bennett, James, and Ohsumi, Shozo
- Subjects
HORMONE receptor positive breast cancer ,METASTATIC breast cancer ,BRCA genes ,EPIDERMAL growth factor receptors - Abstract
Background: The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC).Methods: Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negative MBC within 90 days prior to enrollment. Hormone receptor (HR)-positive patients had experienced disease progression on or after prior endocrine therapy, or endocrine therapy was considered unsuitable. gBRCAm status was determined using baseline blood samples or prior germline test results. For patients with a negative gBRCAm test, archival tissue was tested for somatic BRCAm and homologous recombination repair mutations (HRRm). Details of first-line cytotoxic chemotherapy were also collected.Results: Between March 2017 and April 2018, 384 patients from 14 countries were screened and consented to study enrollment; 341 patients were included in the full analysis set (median [range] age at enrollment: 56 [25-89] years; 256 (75.3%) postmenopausal). Overall, 33 patients (9.7%) had a gBRCAm (16 [4.7%] in gBRCA1 only, 12 [3.5%] in gBRCA2 only, and 5 [1.5%] in both gBRCA1 and gBRCA2). gBRCAm prevalence was similar in HR-positive and HR-negative patients. gBRCAm prevalence was 9.0% in European patients and 10.6% in Asian patients and was higher in patients aged ≤ 50 years at initial breast cancer (BC) diagnosis (12.9%) than patients aged > 50 years (5.4%). In patients with any risk factor for having a gBRCAm (family history of BC and/or ovarian cancer, aged ≤ 50 years at initial BC diagnosis, or triple-negative BC), prevalence was 10.4%, versus 5.8% in patients without these risk factors. HRRm prevalence was 14.1% (n = 9/64) in patients with germline BRCA wildtype.Conclusions: Patient demographic and disease characteristics supported the association of a gBRCAm with younger age at initial BC diagnosis and family history of BC and/or ovarian cancer. gBRCAm prevalence in this cohort, not selected on the basis of risk factors for gBRCAm, was slightly higher than previous results suggested. gBRCAm prevalence among patients without a traditional risk factor for harboring a gBRCAm (5.8%) supports current guideline recommendations of routine gBRCAm testing in HER2-negative MBC, as these patients may benefit from poly(ADP-ribose) polymerase (PARP) inhibitor therapy.Trial Registration: NCT03078036 . [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
154. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
- Author
-
Cazzaniga, Marina E., primary, Munzone, Elisabetta, additional, Bocci, Guido, additional, Afonso, Noémia, additional, Gomez, Patricia, additional, Langkjer, Sven, additional, Petru, Edgar, additional, Pivot, Xavier, additional, Sánchez Rovira, Pedro, additional, Wysocki, Piotr, additional, and Torri, Valter, additional
- Published
- 2018
- Full Text
- View/download PDF
155. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience
- Author
-
Pizzuti, Laura, primary, Giordano, Antonio, additional, Michelotti, Andrea, additional, Mazzotta, Marco, additional, Natoli, Clara, additional, Gamucci, Teresa, additional, De Angelis, Claudia, additional, Landucci, Elisabetta, additional, Diodati, Lucrezia, additional, Iezzi, Laura, additional, Mentuccia, Lucia, additional, Fabbri, Agnese, additional, Barba, Maddalena, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Mariani, Luciano, additional, Paris, Ida, additional, Lorusso, Vito, additional, Vallarelli, Simona, additional, Cassano, Alessandra, additional, Aroldi, Francesca, additional, Orlandi, Armando, additional, Moscetti, Luca, additional, Sergi, Domenico, additional, Sarobba, Maria Giuseppina, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Sini, Valentina, additional, Veltri, Enzo, additional, Vaccaro, Angela, additional, Ferrari, Laura, additional, De Tursi, Michele, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Greco, Filippo, additional, Botticelli, Andrea, additional, La Verde, Nicla, additional, Zamagni, Claudio, additional, Rubino, Daniela, additional, Cortesi, Enrico, additional, Magri, Valentina, additional, Pomati, Giulia, additional, Scagnoli, Simone, additional, Capomolla, Elisabetta, additional, Kayal, Ramy, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Cazzaniga, Marina, additional, Laudadio, Lucio, additional, Forciniti, Samantha, additional, Mancini, Maria, additional, Carbognin, Luisa, additional, Seminara, Patrizia, additional, Barni, Sandro, additional, Samaritani, Riccardo, additional, Roselli, Mario, additional, Portarena, Ilaria, additional, Russo, Antonio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Carpano, Silvia, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, De Maria, Ruggero, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional
- Published
- 2018
- Full Text
- View/download PDF
156. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE
- Author
-
Leo, Silvana, primary, Arnoldi, Ermenegildo, additional, Repetto, Lazzaro, additional, Coccorullo, Zaira, additional, Cinieri, Saverio, additional, Fedele, Palma, additional, Cazzaniga, Marina, additional, Lorusso, Vito, additional, Latorre, Agnese, additional, Campanella, Giovanna, additional, Ciccarese, Mariangela, additional, Accettura, Caterina, additional, Pisconti, Salvatore, additional, Rinaldi, Antonio, additional, Brunetti, Cosimo, additional, Raffaele, Mimma, additional, Coltelli, Luigi, additional, Spazzapan, Salvatore, additional, Fratino, Lucia, additional, Petrucelli, Luciana, additional, and Biganzoli, Laura, additional
- Published
- 2018
- Full Text
- View/download PDF
157. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
- Author
-
Cazzaniga, Marina, primary, Verusio, Claudio, additional, Ciccarese, Mariangela, additional, Fumagalli, Alberto, additional, Sartori, Donata, additional, Valerio, Maria Rosaria, additional, Airoldi, Mario, additional, Moretti, Gabriella, additional, Ficorella, Corrado, additional, Arcangeli, Valentina, additional, Diodati, Lucrezia, additional, Zambelli, Alberto, additional, Febbraro, Antonio, additional, Generali, Daniele, additional, Pistelli, Mirco, additional, Garrone, Ornella, additional, Musolino, Antonino, additional, Vici, Patrizia, additional, Maur, Michela, additional, Mentuccia, Lucia, additional, La Verde, Nicla, additional, Bianchi, Giulia, additional, Artale, Salvatore, additional, Blasi, Livio, additional, Piezzo, Matilde, additional, Atzori, Francesco, additional, Turletti, Anna, additional, Benedetto, Chiara, additional, Cursano, Maria Concetta, additional, Fabi, Alessandra, additional, Gebbia, Vittorio, additional, Schirone, Alessio, additional, Palumbo, Raffaella, additional, Ferzi, Antonella, additional, Frassoldati, Antonio, additional, Scavelli, Claudio, additional, Clivio, Luca, additional, and Torri on behalf of The EVA Study Group, Valter, additional
- Published
- 2018
- Full Text
- View/download PDF
158. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
- Author
-
Cazzaniga, Marina E., primary, Munzone, Elisabetta, additional, Montagna, Emilia, additional, and Pappagallo, Giovanni, additional
- Published
- 2018
- Full Text
- View/download PDF
159. Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
- Author
-
Cerrito, Maria Grazia, primary, De Giorgi, Marco, additional, Pelizzoni, Davide, additional, Bonomo, Sara Maria, additional, Digiacomo, Nunzio, additional, Scagliotti, Arianna, additional, Bugarin, Cristina, additional, Gaipa, Giuseppe, additional, Grassilli, Emanuela, additional, Lavitrano, Marialuisa, additional, Giovannoni, Roberto, additional, Bidoli, Paolo, additional, and Cazzaniga, Marina Elena, additional
- Published
- 2018
- Full Text
- View/download PDF
160. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
- Author
-
De Placido, Sabino, primary, Gallo, Ciro, additional, De Laurentiis, Michelino, additional, Bisagni, Giancarlo, additional, Arpino, Grazia, additional, Sarobba, Maria Giuseppa, additional, Riccardi, Ferdinando, additional, Russo, Antonio, additional, Del Mastro, Lucia, additional, Cogoni, Alessio Aligi, additional, Cognetti, Francesco, additional, Gori, Stefania, additional, Foglietta, Jennifer, additional, Frassoldati, Antonio, additional, Amoroso, Domenico, additional, Laudadio, Lucio, additional, Moscetti, Luca, additional, Montemurro, Filippo, additional, Verusio, Claudio, additional, Bernardo, Antonio, additional, Lorusso, Vito, additional, Gravina, Adriano, additional, Moretti, Gabriella, additional, Lauria, Rossella, additional, Lai, Antonella, additional, Mocerino, Carmela, additional, Rizzo, Sergio, additional, Nuzzo, Francesco, additional, Carlini, Paolo, additional, Perrone, Francesco, additional, Accurso, Antonello, additional, Agostara, Biagio, additional, Aieta, Michele, additional, Alabiso, Oscar, additional, Alicicco, Maria Grazia, additional, Amadori, Dino, additional, Amaducci, Laura, additional, Amiconi, Gianna, additional, Antuzzi, Giustino, additional, Ardine, Mara, additional, Ardizzoia, Antonio, additional, Aversa, Caterina, additional, Badalamenti, Giuseppe, additional, Barni, Sandro, additional, Basurto, Carlo, additional, Berardi, Rossana, additional, Bergamasco, Cinzia, additional, Bidoli, Paolo, additional, Bighin, Claudia, additional, Biondi, Edoardo, additional, Boni, Corrado, additional, Borgonovo, Karen, additional, Botta, Mario, additional, Bravi, Stefano, additional, Bruzzi, Paolo, additional, Buono, Giuseppe, additional, Butera, Alfredo, additional, Caldara, Alessia, additional, Candeloro, Giampiero, additional, Cappelletti, Claudia, additional, Cardalesi, Cinzia, additional, Carfora, Elisabetta, additional, Cariello, Anna, additional, Carrozza, Francesco, additional, Cartenì, Giacomo, additional, Caruso, Michele, additional, Casadei, Virginia, additional, Casanova, Claudia, additional, Castori, Luigi, additional, Cavanna, Luigi, additional, Cavazzini, Giovanna, additional, Cazzaniga, Marina, additional, Chilelli, Mario, additional, Chiodini, Paolo, additional, Chiorrini, Silvia, additional, Ciardiello, Fortunato, additional, Ciccarese, Mariangela, additional, Cinieri, Saverio, additional, Clerico, Mario, additional, Coccaro, Mariarosa, additional, Comande, Mario, additional, Corbo, Claudia, additional, Cortino, Giuseppina, additional, Cusenza, Stefania, additional, Daniele, Gennaro, additional, D'arco, Alfonso Maria, additional, D'auria, Giuliana, additional, Dazzi, Claudio, additional, De Angelis, Carmine, additional, de Braud, Filippo, additional, De Feo, Gianfranco, additional, De Matteis, Andrea, additional, De Tursi, Michele, additional, Di Blasio, Anna, additional, di Lucca, Giuseppe, additional, Di Lullo, Liberato, additional, Di Rella, Francesca, additional, Di Renzo, Gianfranco, additional, Di Stefano, Pia, additional, Di Stefano, Aida, additional, Diana, Anna, additional, Donati, Sara, additional, Fabbri, Agnese, additional, Fabi, Alessandra, additional, Faedi, Marina, additional, Farina, Gabriella, additional, Farris, Antonio, additional, Febbraro, Antonio, additional, Fedele, Palma, additional, Federico, Piera, additional, Ferraù, Francesco, additional, Ferretti, Gianluigi, additional, Ferro, Antonella, additional, Floriani, Irene, additional, Forcignanò, Rosachiara, additional, Forciniti, Samantha, additional, Forestieri, Valeria, additional, Fornari, Gianni, additional, Frisinghelli, Michela, additional, Fusco, Vittorio, additional, Gallizzi, Giulia, additional, Galvano, Antonio, additional, Gambardella, Antonio, additional, Gambi, Angelo, additional, Gebbia, Vittorio, additional, Gervasi, Erika, additional, Ghilardi, Mara, additional, Giacobino, Alice, additional, Giardina, Giovanni, additional, Giotta, Francesco, additional, Giraudi, Sara, additional, Giuliano, Mario, additional, Grassadonia, Antonino, additional, Grasso, Donatella, additional, Grosso, Federica, additional, Guizzaro, Lorenzo, additional, Incoronato, Pasquale, additional, Incorvaia, Lorena, additional, Iodice, Giovanni, additional, La Verde, Nicla, additional, Labonia, Vincenzo, additional, Landi, Gabriella, additional, Latorre, Agnese, additional, Leonardi, Vita, additional, Levaggi, Alessia, additional, Limite, Gennaro, additional, Lina Bascialla, Linda, additional, Livi, Lorenzo, additional, Maiello, Evaristo, additional, Mandelli, Daniela, additional, Marcon, Ilaria, additional, Menon, Daniela, additional, Montedoro, Michele, additional, Moraca, Lucia, additional, Moretti, Anna, additional, Morritti, Maria Grazia, additional, Morselli, Patrizia, additional, Mura, Antonella, additional, Mura, Silvia, additional, Musacchio, Michela, additional, Muzio, Alberto, additional, Natale, Donato, additional, Natoli, Clara, additional, Nigro, Cinzia, additional, Nisticò, Cecilia, additional, Nuzzo, Antonio, additional, Orditura, Michele, additional, Orlando, Laura, additional, Pacilio, Carmen, additional, Palumbo, Giuliano, additional, Palumbo, Raffaella, additional, Pasini, Felice, additional, Paterno, Emanuela, additional, Pazzola, Antonio, additional, Pelliccioni, Silvia, additional, Pensabene, Matilde, additional, Perroni, Davide, additional, Pesenti Gritti, Angela, additional, Petrelli, Fausto, additional, Piccirillo, Maria Carmela, additional, Pinotti, Graziella, additional, Pogliani, Claudia, additional, Poli, Davide, additional, Prader, Sonia, additional, Recchia, Francesco, additional, Rizzi, Daniele, additional, Romano, Carmen, additional, Rossello, Rosalba, additional, Rossini, Chiara, additional, Salvucci, Giuseppina, additional, Sanna, Valeria, additional, Santini, Alessandra, additional, Saracchini, Silvana, additional, Savastano, Clementina, additional, Scambia, Giovanni, additional, Schettini, Francesco, additional, Schiavone, Paola, additional, Schirone, Alessio, additional, Seles, Elena, additional, Signoriello, Simona, additional, Signoriello, Giuseppe, additional, Silva, Rosa Rita, additional, Silvestri, Antonia, additional, Simeon, Vittorio, additional, Spagnoletti, Ilaria, additional, Tamberi, Stefano, additional, Teragni, Cristina, additional, Thalmann, Verena, additional, Thomas, Renato, additional, Thomas, Guglielmo, additional, Tienghi, Amelia, additional, Tinari, Nicola, additional, Tinessa, Vincenza, additional, Tomei, Federica, additional, Tonini, Giuseppe, additional, Torri, Valter, additional, Traficante, Divina, additional, Tudini, Marianna, additional, Turazza, Monica, additional, Vignoli, Roberto, additional, Vitale, Maria Giuseppa, additional, Zacchia, Alessandra, additional, Zagarese, Pasquale, additional, Zanni, Alda, additional, Zavallone, Laura, additional, Zavettieri, Maria, additional, and Zoboli, Alessandra, additional
- Published
- 2018
- Full Text
- View/download PDF
161. Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study.
- Author
-
Cerrito, M, De Giorgi, M, Pelizzoni, D, Bonomo, S, Digiacomo, N, Scagliotti, A, Bugarin, C, Gaipa, G, Grassilli, E, Lavitrano, M, Giovannoni, R, Bidoli, P, Cazzaniga, M, Cerrito, Maria Grazia, De Giorgi Marco, Pelizzoni, Davide, Bonomo, Sara Maria, Digiacomo, Nunzio, Scagliotti, Arianna, Bugarin, Cristina, Gaipa, Giuseppe, Grassilli, Emanuela, Lavitrano, Marialuisa, Giovannoni, Roberto, Bidoli, Paolo, Cazzaniga, Marina Elena, Cerrito, M, De Giorgi, M, Pelizzoni, D, Bonomo, S, Digiacomo, N, Scagliotti, A, Bugarin, C, Gaipa, G, Grassilli, E, Lavitrano, M, Giovannoni, R, Bidoli, P, Cazzaniga, M, Cerrito, Maria Grazia, De Giorgi Marco, Pelizzoni, Davide, Bonomo, Sara Maria, Digiacomo, Nunzio, Scagliotti, Arianna, Bugarin, Cristina, Gaipa, Giuseppe, Grassilli, Emanuela, Lavitrano, Marialuisa, Giovannoni, Roberto, Bidoli, Paolo, and Cazzaniga, Marina Elena
- Abstract
Triple Negative Breast Cancer (TNBC) is an aggressive neoplasia with median Overall Survival (OS) less than two years. Despite the availability of new drugs, the chance of survival of these patients did not increase. The combination of low doses of drugs in a metronomic schedule showed efficacy in clinical trials, exhibiting an anti-proliferative and anti-tumour activity. In Victor-2 study we recently evaluated a new metronomic combination (mCHT) of Capecitabine (CAPE) and Vinorelbine (VNR) in breast cancer patients showing a disease control rate with a median Progression- Free Survival (PFS) of 4.7 months in 28 TNBC patients. Here in Victor-0 study, we examined the effect of mCHT vs standard (STD) schedule of administration of different combinations of 5-Fluorouracil (5FU), the active metabolite of CAPE, and VNR in TNBC cell lines MDA-MB-231 and BT-549. A significant antiproliferative activity was observed in cells treated with metronomic vs STD administration of 5FU or VNR alone. Combination of the two drugs showed an additive inhibitor effect on cell growth in both cell lines . Moreover, after exposure of cells to 5FU and VNR under mCHT or conventional schedule of administration we also observed a downregulation of chemoresistance factor Bcl-2, changes in pro-apoptotic protein Bax and in cleaved effector caspase-3 and increased expression of LC3A/B autophagy protein. Our results therefore suggest that molecular mechanisms implicated in apoptosis and autophagy as well as the cross-talk between these two forms of cell death in MDA-MB-231 and BT-549 cells treated with 5FU and VNR is dose- and scheduledependent and provide some insights about the roles of autophagy and senescence in 5FU/VNR-induced cell death
- Published
- 2018
162. NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study
- Author
-
Cazzaniga, Marina Elena, primary, Mustacchi, Giorgio, additional, Bria, Emilio, additional, Bisagni, Giancarlo, additional, Biganzoli, Laura, additional, Pronzato, Paolo, additional, De Placido, Sabino, additional, Romagnoli, Emanuela, additional, Montemurro, Filippo, additional, Marchetti, Paolo, additional, De Laurentis, Michelino, additional, Riccardi, Ferdinando, additional, Turletti, Anna, additional, Michelotti, Andrea, additional, Natoli, Clara, additional, Livi, Lorenzo, additional, Del Mastro, Lucia, additional, Donadio, Michela, additional, Garrone, Ornella, additional, and Giordano, Monica, additional
- Published
- 2017
- Full Text
- View/download PDF
163. Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 Study
- Author
-
Cazzaniga, Marina Elena, primary, Cagossi, Katia, additional, Valerio, Maria Rosaria, additional, Russo, Salvatore, additional, Casadei, Virginia, additional, Scognamiglio, Giovanni, additional, Cavanna, Luigi, additional, Toniolo, Davide, additional, Deconciliis, Erico Maria Romani, additional, Melegari, Elisabetta, additional, Stocchi, Lucia, additional, Gebbia, Vittorio, additional, Vandone, Anna Maria, additional, Cursano, Maria Concetta, additional, Pinotti, Graziella, additional, Rossello, Rosalba, additional, Ortu, Salvatorico, additional, Pellegrino, Benedetta, additional, Saracchini, Silvana, additional, Pedroli, Stefania, additional, and Torri, Valter, additional
- Published
- 2017
- Full Text
- View/download PDF
164. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
- Author
-
Gligorov, J., primary, Ataseven, B., additional, Verrill, M., additional, De Laurentiis, M., additional, Jung, K.H., additional, Azim, H.A., additional, Al-Sakaff, N., additional, Lauer, S., additional, Shing, M., additional, Pivot, X., additional, Koroveshi, Dhurata, additional, Bouzid, Kamel, additional, Casalnuovo, Monica, additional, Cascallar, Diana, additional, Korbenfeld, Ernesto Pablo, additional, Bastick, Patricia, additional, Beith, Jane, additional, Colosimo, Maree, additional, Friedlander, Michael, additional, Ganju, Vinod, additional, Green, Michael, additional, Patterson, Kevin, additional, Redfern, Andrew, additional, Richardson, Gary, additional, Ceric, Timur, additional, Gordana, Kecman, additional, Beato, Carlos Augusto, additional, Ferrari, Marcela, additional, Hegg, Roberto, additional, Helena, Vanessa, additional, Ismael, Gustavo Fernando, additional, Lessa, Alvaro Edson, additional, Mano, Max, additional, Morelle, Alessandra, additional, Nogueira, Jose Alberto, additional, Timcheva, Konstanta, additional, Tomova, Antoaneta, additional, Tsakova, Maya, additional, Zlatareva-Petrova, Ani, additional, Asselah, Jamil, additional, Assi, Hazem, additional, Brezden-Masley, Christine, additional, Chia, Stephen, additional, Freedman, Ori, additional, Harb, Mohammed, additional, Joy, Anil Abraham, additional, Kulkarni, Swati, additional, Prady, Catherine, additional, Gaete, Alejandro Andres Acevedo, additional, Matamala, Luis, additional, Torres, Roberto, additional, Yanez, Eduardo, additional, Franco, Sandra, additional, Urrego, Marcela, additional, Gugić, Damir, additional, Vrbanec, Damir, additional, Melichar, Bohuslav, additional, Prausová, Jana, additional, Vyzula, Rostislav, additional, Pilarte, Rafael Gutierrez, additional, León, María Isabel, additional, Muñoz, Rene, additional, Ramos, Glenda, additional, Azeem, Hamdy Abdel, additional, Aziz, Amr Abdel, additional, El Zawahry, Heba, additional, Osegueda, Finlander Rosales, additional, Alexandre, Jerome, additional, Artignan, Xavier, additional, Barletta, Hugues, additional, Beguier, Emmanuel, additional, Berdah, Jean-François, additional, Marty, Chantal Bernard, additional, Bollet, Marc, additional, Bourgeois, Hugues, additional, Bressac, Claude, additional, Burki, Franck, additional, Campone, Mario, additional, Coeffic, David, additional, Cojocarasu, Oana Zveltlana, additional, Dagada, Corinne, additional, Dalenc, Florence, additional, Del Piano, Francesco, additional, Desauw, Christophe, additional, Desmoulins, Isabelle, additional, Dohollou, Nadine, additional, Egreteau, Joelle, additional, Ferrero, Jean-Marc, additional, Foa, Cyril, additional, Garidi, Reda, additional, Gasnault, Laurent, additional, Gligorov, Joseph, additional, Guardiola, Emmanuel, additional, Hamizi, Salima, additional, Jarcau, Rosana, additional, Jacquin, Jean-Philippe, additional, Jaubert, Dominique, additional, Jolimoy, Geneviève, additional, Mineur, Hortense Laharie, additional, Largillier, Remy, additional, Leduc, Bernard, additional, Martin, Philippe, additional, Melis, Adrien, additional, Monge, Jeremy, additional, Moullet, Isabelle, additional, Mousseau, Mireille, additional, Nguyen, Suzanne, additional, Orfeuvre, Hubert, additional, Petit, Thierry, additional, Pivot, Xavier, additional, Priou, Frank, additional, Bach, Isabelle Sillet, additional, Simon, Helene, additional, Stefani, Laetitia, additional, Uwer, Lionel, additional, Youssef, Ali, additional, Aktas, Bahriye, additional, von der Assen, Albert, additional, Augustin, Doris, additional, Balser, Christina, additional, Bauer, Lelia-Eveline, additional, Bechtner, Christina, additional, Beyer, Greta, additional, Brucker, Cosima, additional, Bückner, Ute, additional, Busch, Steffi, additional, Christensen, Bernd, additional, Deryal, Mustafa, additional, Farrokh, Andre, additional, Faust, Elke, additional, Friedrichs, Kay, additional, Graf, Heiko, additional, Griesshammer, Martin, additional, Grischke, Eva-Maria, additional, Hänle, Claudia, additional, Heider, Andrea, additional, Henschen, Stephan, additional, Hesse, Tobias, additional, Jackisch, Christian, additional, Kisro, Jens, additional, Köhler, Andreas, additional, Kuemmel, Sherko, additional, Lampe, Dieter, additional, Lantzsch, Tilmann, additional, Latos, Kunibert, additional, Lex, Benno, additional, Liedtke, Cornelia, additional, Luedders, Doerte, additional, Maintz, Christoph, additional, Müller, Volkmar, additional, Overkamp, Friedrich, additional, Park-Simon, Tjoung-won, additional, Paul, Marion, additional, Prechtl, Anita, additional, Ringsdorf, Uta, additional, Runnebaum, Ingo, additional, Ruth, Sylvia, additional, Salat, Christoph, additional, Scheffen, Iris, additional, Schilling, Jörg, additional, Schmatloch, Sabine, additional, Schmidt, Marcus, additional, Schneeweiss, Andreas, additional, Schrader, Iris, additional, Seipelt, Gernot, additional, Simon, Elke, additional, Stefek, Andrea, additional, Stickeler, Elmar, additional, Thill, Marc, additional, Tio, Joke, additional, Tuczek, Anna, additional, Warm, Mathias, additional, Weigel, Michael, additional, Wischnik, Arthur, additional, Wojcinski, Sebastian, additional, Ziegler-Löhr, Katja, additional, Aravantinos, Gerasimos, additional, Ardavanis, Alexandros, additional, Fountzilas, George, additional, Gogas, Helen, additional, Kakolyris, Stylianos, additional, Mavroudis, Dimitris, additional, Papadimitriou, Christos, additional, Papandreou, Christos, additional, Papazisis, Konstantinos, additional, Castro, Hugo, additional, Hernandez-Monroy, Cesar Estuardo, additional, Ngan, Roger, additional, Yeo, Winnie, additional, Bittner, Nora, additional, Boer, Katalin, additional, Csejtei, Andras, additional, Horvath, Zsolt, additional, Kocsis, Judit, additional, Mangel, László Csaba, additional, Mezei, Klara, additional, Nagy, Zsuzsanna, additional, Szanto, Janos, additional, Atmakusuma, Djumhana, additional, Fadjari, Heri, additional, Kurnianda, Djohan, additional, Prayogo, Nugroho, additional, Tanggo, Eddie Herman, additional, Coate, Linda, additional, Hennessy, Bryan, additional, Kelly, Cathy, additional, Martin, Michael, additional, Nasim, Saira, additional, O'Connor, Miriam, additional, Aieta, Michele, additional, Allegrini, Giacomo, additional, Amadori, Dino, additional, Bidoli, Paolo, additional, Biti, Giampaolo, additional, Bordonaro, Roberto, additional, Bottini, Alberto, additional, Carterni, Giacomo, additional, Cavanna, Luigi, additional, Cazzaniga, Marina, additional, Cognetti, Francesco, additional, Contu, Antonio, additional, Cruciani, Giorgio, additional, Donadio, Michela, additional, Falcone, Alfredo, additional, Farci, Daniele, additional, Forcignanò, R. Chiara, additional, Frassoldati, Antonio, additional, Gaion, Fernando, additional, Gamucci, Teresa, additional, Giotta, Francesco, additional, de Laurentiis, Michele, additional, Livi, Lorenzo, additional, Lorusso, Vito, additional, Maiello, Evaristo, additional, Marchetti, Paolo, additional, Mariani, Gabriella, additional, Mion, Marta, additional, Moscetti, Luca, additional, Musolino, Antonino, additional, Pazzola, Antonio, additional, Pedrazzoli, Paolo, additional, Pigi, Andrea, additional, de Placido, Sabino, additional, Caremoli, Elena Rota, additional, Santoro, Armando, additional, Tienghi, Amelia, additional, Ahn, Jin-Seok, additional, Jung, Kyung Hae, additional, Lee, Keun Seok, additional, Lee, Soo Hyeon, additional, Seo, Jae Hong, additional, Sohn, Joo-Hyuk, additional, Cesas, Alvydas, additional, Juozaityte, Elona, additional, Cheah, Nellie Lay Chin, additional, Chong, Flora Li Tze, additional, Devi, Beena C.R., additional, Phua, Vincent, additional, Teoh, Darren, additional, Ching, Lee Wei, additional, Yusof, Mastura, additional, Corona, Jorge, additional, Dominguez, Adriana, additional, Mendoza, René Lazaro González, additional, Hernandez, Carlos Alberto, additional, Ramiro, Alejandro Juarez, additional, Santos, Juan Matos, additional, Espinosa, Paola Morales, additional, Villarreal Garza, Cynthia Mayte, additional, Errihani, Hassan, additional, Bakker, Sandra, additional, van den Berkmortel, Franchette, additional, Blaisse, R.J.B., additional, Huinink, Daan ten Bokkel, additional, van den Bosch, J., additional, Braun, J.J., additional, Dercksen, M.W., additional, Droogendijk, Helga, additional, Erdkamp, Frans, additional, Haringhuizen, Annebeth, additional, de Jongh, F.E., additional, Kok, T.C., additional, Los, Maartje, additional, Madretsma, Stanley, additional, Terwogt, Jetske M. Meerum, additional, van der Padt, Annemieke, additional, van Rossum-Schornagel, Quirine Clementine, additional, Smilde, T.J., additional, de Valk, Bart, additional, van der Velden, Annette, additional, van Warmerdam, Laurence, additional, van de Wouw, A.J., additional, North, Richard, additional, Kersten, Christian, additional, Mjaaland, Ingvild, additional, Wist, Erik, additional, Aziz, Zeba, additional, Masood, Nehal, additional, Rashid, Kamran, additional, Shah, Mazhar, additional, Alcedo, Juan Carlos, additional, Aleman, Diana, additional, Neciosup, Silvia, additional, Reategui, Rocio, additional, Valdiviezo, Natalia, additional, Vera, Luis, additional, Fernando, Gracieux, additional, Roque, Fernando, additional, Strebel, Heinrik Martin, additional, Krzemieniecki, Krzysztof, additional, Litwiniuk, Maria, additional, Mruk, Andrzej, additional, Pienkowski, Tadeusz, additional, Sawrycki, Piotr, additional, Slomian, Grzegorz, additional, Tomczak, Piotr, additional, Afonso, Noemia, additional, Cardoso, Fátima, additional, Damasceno, Margarida, additional, Nave, Monica, additional, Badulescu, Florinel, additional, Ciule, Larisa, additional, Curescu, Stefan, additional, Eniu, Alexandru, additional, Filip, Dumitru, additional, Grecea, Daniela, additional, Jinga, Dan-Corneliu, additional, Lungulescu, Dan, additional, Oprean, Cristina Marinela, additional, Stanculeanu, Dana Lucia, additional, Turdean, Maria, additional, Dvornichenko, Viktoria, additional, Emelyanov, Sergey, additional, Lichinitser, Mikhail, additional, Manikhas, Alexey, additional, Sakaeva, Dina, additional, Shirinkin, Vadim, additional, Stroyakovskiy, Daniil, additional, Abulkhair, Omalkhair, additional, Zekri, Jamal, additional, Filipovic, Sladjana, additional, Kovcin, Vladimir, additional, Nedovic, Jasmina, additional, Pesic, Jasna, additional, Vasovic, Suzana, additional, Ng, Raymond, additional, Bystricky, Branislav, additional, Leskova, Jaroslava, additional, Mardiak, Jozef, additional, Mišurová, Etela, additional, Wagnerova, Maria, additional, Takač, Iztok, additional, Demetriou, Georgia Savva, additional, Dreosti, Lydia, additional, Govender, Poovandren, additional, Jordaan, Johannes Petrus, additional, Veersamy, Petrosian, additional, Romero, Jose Luis Alonso, additional, Lopez, Norberto Batista, additional, Arias, Carmen Cañabate, additional, Chacon, Jose, additional, Aramburo, Antonio Fernandez, additional, Morales, Luis Antonio Fernandez, additional, Garcia, Mirta, additional, Estevez, Laura Garcia, additional, Garcia-Palomo Perez, Andres, additional, Garcia Saenz, Jose Angel, additional, Garcia Sanchis, Laura, additional, Cubells, Laia Garrigos, additional, Cortijo, Lucia Gonzalez, additional, Santiago, Santiago Gonzalez, additional, De Aranguiz, Blanca Hernando Fernandez, additional, Mañas, José Juan Illarramendi, additional, Gallego, Pedro Jimenez, additional, Cussac, Antonio Llombart, additional, Ferrandiz, Cristina Llorca, additional, Garrido, Maria Lomas, additional, Alvarez, Pilar Lopez, additional, Vega, Jose Manuel Lopez, additional, Del Prado, Purificacion Martinez, additional, Jañez, Noelia Martinez, additional, Murillo, Serafin Morales, additional, Rosales, Adolfo Murias, additional, Jaso, Laura Murillo, additional, Fernandez, Ignacio Pelaez, additional, Martorell, Antonia Perello, additional, Carrion, Ramon Perez, additional, Simon, Sonia Pernas, additional, Alcibar, Arrate Plazaola, additional, Lorenzo, Jose Ponce, additional, Garcia, Vanesa Quiroga, additional, Asensio, Teresa Ramon y Cajal, additional, Maicas, Maria Dolores Torregrosa, additional, Villanueva Silva, Maria Jose, additional, Killander, Fredrika, additional, Svensson, Jan Henry, additional, Fehr, Mathias, additional, Hauser, Nik, additional, Müller, Andreas, additional, Pagani, Olivia, additional, Passmann-Kegel, Heike, additional, Popescu, Razvan, additional, Rabaglio, Manuela, additional, Rauch, Daniel, additional, Schlatter, Christina, additional, Zaman, Khalil, additional, Chang, Tsai-Wang, additional, Huang, Chiun-Sheng, additional, Wang, Hwei-Chung, additional, Yu, Jyh-Cherng, additional, Bandidwattanawong, Chanyoot, additional, Maneechavakajorn, Jedzada, additional, Seetalarom, Kasan, additional, Dejthevaporn, Thitiya (Sirisinha), additional, Somwangprasert, Areewan, additional, Vongsaisuwon, Mawin, additional, Akbulut, Hakan, additional, Altundag, Kadri, additional, Arican, Ali, additional, Bozcuk, Hakan, additional, Eralp, Yesim, additional, Idris, Mohamed, additional, Isikdogan, Abdurrahman, additional, Senol, Coskun Hasan, additional, Sevinc, Alper, additional, Uygun, Kazim, additional, Yucel, Eftal, additional, Yucel, Idris, additional, Yumuk, Fulden, additional, Shparyk, Yaroslav, additional, Voitko, Nataliia, additional, Jaloudi, Mohammed, additional, Adams, Jocelyn, additional, Agrawal, Rajiv, additional, Ahmed, Samreen, additional, Alhasso, Abdulla, additional, Allerton, Rozenn, additional, Anwar, Suhail, additional, Archer, Caroline, additional, Ashford, Richard, additional, Barraclough, Lisa, additional, Bertelli, Gianfilippo, additional, Bishop, Jill, additional, Branson, Tony, additional, Butt, Mohammed, additional, Chakrabarti, Amit, additional, Chakraborti, Prabir, additional, Churn, Mark, additional, Crowley, Clare, additional, Davis, Ruth, additional, Dhadda, Amandeep, additional, Eldeeb, Hany, additional, Fraser, Judith, additional, Hall, Julia, additional, Hickish, Tamas, additional, Hogg, Martin, additional, Howe, Theresa, additional, Joffe, Jonathan, additional, Kelleher, Muireann, additional, Kelly, Stephen, additional, Kendall, Anne, additional, Kristeleit, Hartmut, additional, Lumsden, Graeme, additional, Macmillan, Craig, additional, MacPherson, Iain, additional, Malik, Zafar, additional, Mithal, Natasha, additional, Neal, Anthony, additional, Panwar, Udaiveer, additional, Proctor, Andrew, additional, Proctor, Steven John, additional, Raj, Sanjay, additional, Rehman, Shazza, additional, Sandri, Ines, additional, Scatchard, Kate, additional, Sherwin, Elizabeth, additional, Sims, Eliot, additional, Singer, Julian, additional, Smith, Sarah, additional, Tahir, Saad, additional, Taylor, Wendy, additional, Tsalic, Medy, additional, Verrill, Mark, additional, Wardley, Andrew, additional, Waters, Simon, additional, Wheatley, Duncan, additional, Wright, Kathryn, additional, Yuille, Frances, additional, Alonso, Isabel, additional, Artagaveytia, Nora, additional, Rodriguez, Robinson, additional, Arbona, Esther, additional, Garcia, Yuraima, additional, Lion, Lorena, additional, Marcano, Dalila, additional, and Van Thuan, Tran, additional
- Published
- 2017
- Full Text
- View/download PDF
165. Is metronomic vinorelbine (mVRL) able to inhibit both HUVEC and triple-negative breast cancer (TNBC) cells? The proof-of-concept VICTOR-0 study.
- Author
-
Cerrito, Maria Grazia, primary, Pelizzoni, Davide, additional, De Giorgi, Marco, additional, Digiacomo, Nunzio, additional, Lavitrano, Marialuisa, additional, Giovannoni, Roberto, additional, Bidoli, Paolo, additional, and Cazzaniga, Marina Elena, additional
- Published
- 2017
- Full Text
- View/download PDF
166. From the CLEOPATRA study to real life: An observational study from 11 Italian Centres; Preliminary report from the G.O.N.O. SUPER trial.
- Author
-
Garrone, Ornella, primary, Saggia, Chiara, additional, Beano, Alessandra, additional, Cicchiello, Federica, additional, Milani, Andrea, additional, Bertolini, Ilaria, additional, Coltelli, Luigi, additional, La Verde, Nicla Maria, additional, Collovà, Elena, additional, De Conciliis, Enrico, additional, Pedani, Fulvia, additional, Vandone, Anna Maria, additional, Donadio, Michela, additional, Cazzaniga, Marina Elena, additional, Michelotti, Andrea, additional, and Merlano, Marco Carlo, additional
- Published
- 2017
- Full Text
- View/download PDF
167. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting
- Author
-
Generali, Daniele, primary, Montemurro, Filippo, additional, Bordonaro, Roberto, additional, Mafodda, Antonino, additional, Romito, Sante, additional, Michelotti, Andrea, additional, Piovano, Pierluigi, additional, Ionta, Maria Teresa, additional, Bighin, Claudia, additional, Sartori, Donata, additional, Frassoldati, Antonio, additional, Cazzaniga, Marina Elena, additional, Riccardi, Ferdinando, additional, Testore, Franco, additional, Vici, Patrizia, additional, Barone, Carlo Antonio, additional, Schirone, Alessio, additional, Piacentini, Federico, additional, Nolè, Franco, additional, Molino, Annamaria, additional, Latini, Luciano, additional, Simoncini, Edda Lucia, additional, Roila, Fausto, additional, Cognetti, Francesco, additional, Nuzzo, Francesco, additional, Foglietta, Jennifer, additional, Minisini, Alessandro Marco, additional, Goffredo, Francesca, additional, Portera, Giuseppe, additional, Ascione, Gilda, additional, and Mariani, Gabriella, additional
- Published
- 2017
- Full Text
- View/download PDF
168. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
- Author
-
Cazzaniga, Marina Elena, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Gianni, Lorenzo, Michelotti, Andrea, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, and Mentuccia, Lucia
- Subjects
ANTINEOPLASTIC agents ,BREAST tumors ,CANCER patients ,DOSE-response relationship in biochemistry ,METASTASIS ,TREATMENT effectiveness ,TREATMENT duration ,DESCRIPTIVE statistics - Abstract
Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35–82) for the EVA and 57.8 years (range 35.0–82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1–48) and 12.4 months (range 2.9–70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
169. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE.
- Author
-
Leo, Silvana, Arnoldi, Ermenegildo, Repetto, Lazzaro, Coccorullo, Zaira, Cinieri, Saverio, Fedele, Palma, Cazzaniga, Marina, Lorusso, Vito, Latorre, Agnese, Campanella, Giovanna, Ciccarese, Mariangela, Accettura, Caterina, Pisconti, Salvatore, Rinaldi, Antonio, Brunetti, Cosimo, Raffaele, Mimma, Coltelli, Luigi, Spazzapan, Salvatore, Fratino, Lucia, and Petrucelli, Luciana
- Subjects
BREAST cancer prognosis ,ERIBULIN ,ELDER care ,GERIATRIC assessment ,BREAST tumors ,CANCER chemotherapy ,CANCER relapse ,MEDICAL cooperation ,METASTASIS ,SCIENTIFIC observation ,QUALITY of life ,QUESTIONNAIRES ,RESEARCH ,ACTIVITIES of daily living ,TERMINATION of treatment ,VISUAL analog scale ,TREATMENT effectiveness ,GERIATRIC Depression Scale ,OLD age ,THERAPEUTICS - Abstract
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
170. In reply to Kadri Altundag
- Author
-
Cazzaniga, Marina E., primary
- Published
- 2016
- Full Text
- View/download PDF
171. Corrigendum to “Gene expression profiling in breast cancer: A clinical perspective” [The Breast 22 (2013) 109–120]
- Author
-
Arpino, Grazia, primary, Generali, Daniele, additional, Sapino, Anna, additional, Del Mastro, Lucia, additional, Frassoldati, Antonio, additional, de Laurentiis, Michelino, additional, Pronzato, Paolo, additional, Mustacchi, Giorgio, additional, Cazzaniga, Marina, additional, De Placido, Sabino, additional, Conte, Pierfranco, additional, Cappelletti, Mariarosa, additional, Zanoni, Vanessa, additional, Antonelli, Andrea, additional, Martinotti, Mario, additional, Puglisi, Fabio, additional, Berruti, Alfredo, additional, Bottini, Alberto, additional, and Dogliotti, Luigi, additional
- Published
- 2016
- Full Text
- View/download PDF
172. Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.
- Author
-
Cavaletti, Guido, Alberti, Paola, Cazzaniga, Marina E., Cortinovis, Diego, Rossi, Emanuela, Valsecchi, Maria G., Argyriou, Andreas A., Kalofonos, Haralabos P., Briani, Chiara, Campagnolo, Marta, Cacciavillani, Mario, Bruna, Jordi, and Velasco, Roser
- Subjects
OXALIPLATIN ,NEUROPHYSIOLOGIC monitoring ,NEUROTOXICOLOGY ,COLON cancer patients ,BIOLOGICAL tags ,ANTINEOPLASTIC agents ,COLON tumors ,LONGITUDINAL method ,PERIPHERAL neuropathy ,ORGANOPLATINUM compounds ,RECTUM tumors ,RESEARCH funding ,SYNDROMES ,TIBIAL nerve ,PHARMACODYNAMICS - Abstract
Purpose: We aimed to verify the predictiveness of dorsal sural nerve neurophysiological monitoring in obtaining risk stratification for oxaliplatin-induced peripheral neurotoxicity (OXAPN).Methods: We conducted a secondary analysis on a cohort of 110 colorectal cancer patients who were evaluated clinically and neurophysiologically before chemotherapy, at mid-treatment and at discontinuation. We applied the classification tree analysis method to predict the end-of-treatment OXAPN neurophysiological diagnosis, using data recorded at mid-treatment. We then ascertained the correlation between the obtained classes and neurological impairment at the end of treatment (Fisher's exact test).Results: Dorsal sural nerve monitoring enabled us to stratify oxaliplatin-treated patients into risk classes with an implemented approach to neurophysiology application in this setting. Neurological outcome at discontinuation was predicted by neurophysiological monitoring performed during chemotherapy administration.Conclusions: We demonstrated the role that neurophysiology may play in clinical trials as an early surrogate marker that can predict OXAPN development at the end of treatment. Specifically, we propose abnormal dorsal sural sensory nerve testing as an early biomarker in identifying patients at high risk of eventually developing OXAPN. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
173. A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the 'Real Life' Population And Actual Dose
- Author
-
ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, BIDOLI, PAOLO, CAVALETTI, GUIDO ANGELO, Alberti, P, Cortinovis, D, Cazzaniga, M, Bidoli, P, and Cavaletti, G
- Subjects
Oxaliplatin, Peripheral Neurotoxicity - Abstract
INTRODUCTION: The real incidence of platinum drugs Chemotherapy Induced Peripheral Neuropathy (CIPN) is yet to be defined. Oxaliplatin (L-OHP) is associated with 2 different neurotoxicity: 1) acute neurotoxicity, (axonal hyperexicitability in days following iv administration with transient symptoms, such as cold-induced paresthesias); 2) chronic neuropathy, (sensory axonal one) which it is suggested to be developed in 10-20% of patients, with a threshold cumulative dose of 800-1000 mg/m2. Here an ongoing study is reported, aimed to better clarify incidence and issue in assessment, taking into account the actual L-OHP dose received by patients. METHODS: Patients eligible to undergo L-OHP based chemotherapy (FOLFOX-4) for colorectal cancer, are being enrolled. Subjects undergo a formal neurological examination, using the clinical version of the Total Neuropathy Score (TNSc), before starting CT (T0), after 6 cycles (T1) and at the end of treatment (T2); a neurophysiological assessment of limb distal nerves is also performed every time and acute toxicity phenomena record is made thorough a specifically designed questionnaire. RESULTS: Here data on 36 consecutive patients are shown. Median age was 62 (42-83); 67% of patients were male. 75% of patients were treated in an adjuvant setting. 6 patients were lost at T1 and 4 at T2, due to L-OHP discontinuation (mainly for hematological toxicities). The actual median cumulative dose was 839,5 (375,7-1021) mg/m2 and actual median dose intensity was 31,02 (14,45-42,50) mg/m2/week. At T0: median TNSc score was 0 (0-5); 17% of patients showed neurophysiological alterations. At T1: median TNSc score was 1 (0-6), 20% of patients showed alterations at neurophysiological assessment; 100% of patients showed at least one acute toxicity symptom. At T2: median score for TNSc was 4,5 (0-11), 73 % of patients showed alterations at neurophysiological assessment; 100% of patients showed at least one acute toxicity symptom. DISCUSSION: The novelty of the study is the accurate neurological assessment (TNSc, neurophysiology, acute symptoms questionnaire), with a concomitant registration of the actual, and not only the planned, doses of L-OHP received by each patient. As expected (but not recorded in the vast majority of the reported studies) the real life population received less than the planned dose (here, 80% of planned cumulative dose and 70% of planned dose intensity). This observation strongly supports the fact that L-OHP threshold dose for CIPN might have been underestimated so far and it suggests the need for a revision of the available data in order to analyse them more reliably.
- Published
- 2012
174. When progressive dysphagia could be related to an 'old friend' – a case report
- Author
-
ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, BIDOLI, PAOLO, FERRARESE, CARLO, Fumagalli, L, Piatti, ML, Santoro, P, Pettinaroli, R, Alberti, P, Fumagalli, L, Piatti, M, Santoro, P, Pettinaroli, R, Cortinovis, D, Cazzaniga, M, Bidoli, P, and Ferrarese, C
- Subjects
Cancer, Metastasis, Neulogical syndromes - Abstract
Clinical case: Here it is presented the case of a 63 years old female patient, which developed a progressive dysphagia. These are main data about her history: mastectomy (in 1997) and subsequent chemotherapy and radiotherapy for breast cancer; adrenal gland adenoma; nontoxic multinodular goiter; colon polyp (adenoma). Since 2009 she was diagnosed with an unilateral vocal cord palsy of undefined origin (neck MRI, brain MRI: negative). In December 2011 she was referred to the emergency ward due to a marked worsening of a progressive dysphagia in the last few months. She was admitted to Otorinolaringoiatric department where FBS demonstrated bilateral vocal cord hypomobility; a nasogastric sondine was placed. She was then transferred to the Neurology department where she underwent an EMG, consistent with a sensory-motor polyneuropathy; some features were also consistent with a Lambert-Eaton syndrome (Ig i.v. were started without response). She underwent a total body CT scan with contrast which was negative, apart from the yet known adrenal gland adenoma. In the mean time her clinical condition worsened: her nutritional state progressively deteriorated and her respiratory function started to become impaired with the necessity of PEG positioning and tracheostomy procedure. She then was studied with a brain MRI with mean of contrast: pathological tissue with enhancement was showed at the level of right jugular foramen, involving nerve fibers. Subsequently a biopsy was performed: histological exam revealed a localization of a breast adenocarcinoma. After completing restaging (no other sites of neoplastic disease were found), she was referred to the Oncology department were she was treated with radiotherapy (60 Gy in 30 fractions) and Letrozole. She was then discharged from the hospital in stable clinical condition; PEG and tracheostomy still placed and necessary. Conclusion: the peculiarity of this clinical case is the particular metastatic disease found, both for its being the only one metastatic localization developed, both for presenting itself after nearly 15 years of negative oncological follow-up, in absence of metastatic disease before the present one. Even more, diagnosis was quite challenging, since it was quite surprising to discover her symptoms were due to a neoplastic disease that was considered as “cured”.
- Published
- 2012
175. Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment
- Author
-
CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, CAVALETTI, GUIDO ANGELO, ALBERTI, PAOLA, Giuntini, N, Canova, S, Bidoli, P, CI Perinoms Study Group, Cortinovis, D, Cazzaniga, M, Cavaletti, G, Giuntini, N, Canova, S, Alberti, P, Bidoli, P, and CI Perinoms Study, G
- Subjects
Chemotherapy Induced Peripheral Neurotoxicity, Neuropathy assessment - Abstract
CIPN) is a dose-limiting adverse event of anticancer drugs. A simple and valid method to assess CIPN has not yet been individuated so far; lack of a gold standard measure is still an unmet clinical and scientific need, in particular mandatory to design consistent neuroprotective trials. This study was performed"to select a valid and reproducible outcome measure among existing scales. Patients and methods. These scales were selected to be tested, after a revision of literature and an expert consensus meeting: National Cancer Institute Common-Toxicity-Criteria (NCI-CTC), Total Neuropathy Score (TNSc), modified INCAT sensory sumscore (mISS), European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and CIPN20 quality of life measures. Two hundred and eighty-one cancer patients, with a proven stable CIPN and no ongoing chemotherapy, were enrolled at 20 EU/US Centers. Each patient was evaluated twice, every time by two neurologists. Inter- and intra-rater agreement was calculated through K-Cohen coefficients and 95% confidence intervals. Validity tests were performed, through Kruskal-Wallis equality-of-populations rank test, relating mISS and TNSc to NCI-CTC grades. Results. From September 2008 to December 2010, 281 patients affected by colorectal, breast, ovarian, non-small cell lung cancer and multiple myeloma were enrolled. Inter-/intra-observer scores (i.e. r >0.7) were obtained for TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were high also for EORTC QLQ-C30 and for the CIPN20. Acceptable validity scores were obtained through for mISS and TNSc compared to NCI-CTC (p values 0.04 to
- Published
- 2012
176. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis
- Author
-
Terrazzino, S, Argyriou, A, Cargnin, S, Antonacopoulou, A, Briani, C, Bruna, J, Velasco, R, Alberti, P, Campagnolo, M, Lonardi, S, Cortinovis, D, Cazzaniga, M, Santos, C, Kalofonos, H, Canonico, P, Genazzani, A, Cavaletti, G, ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, CAVALETTI, GUIDO ANGELO, Terrazzino, S, Argyriou, A, Cargnin, S, Antonacopoulou, A, Briani, C, Bruna, J, Velasco, R, Alberti, P, Campagnolo, M, Lonardi, S, Cortinovis, D, Cazzaniga, M, Santos, C, Kalofonos, H, Canonico, P, Genazzani, A, Cavaletti, G, ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, and CAVALETTI, GUIDO ANGELO
- Abstract
We aimed at validating the role of genetic variants identified by a recent genome-wide association study (GWAS) as determinants of chronic oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Eight polymorphisms (rs10486003, rs2338, rs843748, rs797519, rs4936453, rs12023000, rs17140129, and rs6924717) were genotyped in a total of 150 colorectal cancer patients of Caucasian origin receiving oxaliplatin-based chemotherapy. The severity grade of chronic OXAIPN was assessed by NCI-CTC criteria and the clinical version of the Total Neuropathy Score© (TNSc©). None of the polymorphisms investigated was found associated with grade ≥ chronic OXAIPN (NCI-CTC criteria), while a nominal association emerged for ACYP2 rs843748 when using the TNSc© scale (dominant model: odds ratio [OR]: 0.27, 95% confidence interval [CI]: 0.10-0.75, P=0.008). In the combined analysis of this results with data of the two previously published studies which assessed chronic OXAIPN by NCI-CTC criteria, evidence suggestive of association with chronic OXAIPN (NCI-CTC criteria) was found for ACYP2 rs843748 (dominant model: OR: 2.40, 95%CI: 1.40-5.24, P=0.027), which, however, did not remain significant after correction for multiple testing (threshold P-value <0.00625). These findings suggest a minor role of the single nucleotide polymorphisms (SNPs) investigated as genetic determinants of chronic OXAIPN. These results also highlight the importance of replication studies with meta-analysis for validation of GWAS findings.
- Published
- 2015
177. PO64 METRONOMIC CHEMOTHERAPY (CHT) COMBINATION OF VINORELBINE (VRL) AND CAPECITABINE (CAPE) IN HER2- ADVANCED BREAST CANCER (ABC) PATIENTS (PTS) DOES NOT IMPAIR GLOBAL QOL. FIRST RESULTS OF THE VICTOR-2 STUDY
- Author
-
Elena Cazzaniga, Marina, primary, Torri, Valter, additional, Cortesi, Laura, additional, Clivio, Luca, additional, Ferzi, Antonella, additional, Giovanardi, Filippo, additional, Ciccarese, Mariangela, additional, Pugliese, Palma, additional, Torre, Silvia Della, additional, and Bidoli, Paolo, additional
- Published
- 2015
- Full Text
- View/download PDF
178. Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study
- Author
-
Arpino, Grazia, primary, Michelotti, Andrea, additional, Truini, Mauro, additional, Montemurro, Filippo, additional, Russo, Stefania, additional, Palumbo, Raffaella, additional, Zamagni, Claudio, additional, Latorre, Agnese, additional, Bruzzese, Dario, additional, Riccardi, Ferdinando, additional, De Laurentiis, Michelino, additional, Beano, Alessandra, additional, Biganzoli, Laura, additional, Zaniboni, Alberto, additional, Laudadio, Lucio, additional, Malagoli, Maria, additional, Bilancia, Domenico, additional, Schettini, Francesco, additional, Giuliano, Mario, additional, Cazzaniga, Marina Elena, additional, and De Placido, Sabino, additional
- Published
- 2015
- Full Text
- View/download PDF
179. Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations
- Author
-
Del Mastro, Lucia, primary, Cazzaniga, Marina, additional, Solidoro, Paolo, additional, Generali, Daniele, additional, Bianchi, Giulia, additional, Testore, Franco, additional, and De Placido, Sabino, additional
- Published
- 2015
- Full Text
- View/download PDF
180. "Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children.
- Author
-
Cazzaniga, Marina Elena, primary, Gallina, Francesca, additional, Bani, Marco, additional, Riva, Francesca, additional, Tagliabue, Lorenzo, additional, Bidoli, Paolo, additional, Jankovic, Moncilo, additional, Verusio, Claudio, additional, and Mazza, Umberto, additional
- Published
- 2015
- Full Text
- View/download PDF
181. Abstract P2-12-05: Psychological status of early breast cancer (EBC) patients (pts) after surgery and before the starting of aromatase Inhibitors (AIs). Results of a single-institution, prospective study
- Author
-
Cazzaniga, Marina E, primary, Valentini, Annalisa, additional, Gallina, Francesca, additional, Riva, Francesca, additional, Crippa, Alessandra, additional, Tagliabue, Marco, additional, Cicchiello, Federica, additional, Cortinovis, Diego, additional, and Bidoli, Paolo, additional
- Published
- 2015
- Full Text
- View/download PDF
182. PO84 - NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study
- Author
-
Cazzaniga, Marina Elena, Mustacchi, Giorgio, Bria, Emilio, Bisagni, Giancarlo, Biganzoli, Laura, Pronzato, Paolo, De Placido, Sabino, Romagnoli, Emanuela, Montemurro, Filippo, Marchetti, Paolo, De Laurentis, Michelino, Riccardi, Ferdinando, Turletti, Anna, Michelotti, Andrea, Natoli, Clara, Livi, Lorenzo, Del Mastro, Lucia, Donadio, Michela, Garrone, Ornella, and Giordano, Monica
- Published
- 2017
- Full Text
- View/download PDF
183. PO77 - Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 Study
- Author
-
Cazzaniga, Marina Elena, Cagossi, Katia, Valerio, Maria Rosaria, Russo, Salvatore, Casadei, Virginia, Scognamiglio, Giovanni, Cavanna, Luigi, Toniolo, Davide, Deconciliis, Erico Maria Romani, Melegari, Elisabetta, Stocchi, Lucia, Gebbia, Vittorio, Vandone, Anna Maria, Cursano, Maria Concetta, Pinotti, Graziella, Rossello, Rosalba, Ortu, Salvatorico, Pellegrino, Benedetta, Saracchini, Silvana, Pedroli, Stefania, and Torri, Valter
- Published
- 2017
- Full Text
- View/download PDF
184. First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study.
- Author
-
Piazza, Francesca, Bonelli, Candida, Lui, Stefania, di Nunzio, Camilla, Collova, Elena, Bozzoli, Elisabetta, Vici, Patrizia, Gebbia, Vittorio, Valerio, Maria Rosaria, Zustovich, Fable, Vanella, Paola, Coltelli, Luigi, Pistelli, Mirco, Giotta, Francesco, Torri, Valter, and Cazzaniga, Marina Elena
- Published
- 2023
- Full Text
- View/download PDF
185. The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy.
- Author
-
Alberti, P, Cacciavillani, M, Bruna, J, Roser, V, Briani, C, Campagnolo, M, Roncaletti, S, Cazzaniga, M, Cortinovis, D, Kalofonos, H, Cavaletti, G, Argyriou, A, ALBERTI, PAOLA, CAZZANIGA, MARINA ELENA, CORTINOVIS, DIEGO LUIGI, CAVALETTI, GUIDO ANGELO, Cacciavillani M, Bruna J, Roser V, Kalofonos, HP, Argyriou, AA, Alberti, P, Cacciavillani, M, Bruna, J, Roser, V, Briani, C, Campagnolo, M, Roncaletti, S, Cazzaniga, M, Cortinovis, D, Kalofonos, H, Cavaletti, G, Argyriou, A, ALBERTI, PAOLA, CAZZANIGA, MARINA ELENA, CORTINOVIS, DIEGO LUIGI, CAVALETTI, GUIDO ANGELO, Cacciavillani M, Bruna J, Roser V, Kalofonos, HP, and Argyriou, AA
- Abstract
INTRODUCTION: Thus far, there is no gold standard for the accurate monitoring of Oxaliplatin-induced peripheral neuropathy (OXAIPN). For anatomical reasons, Dorsal Sural Nerve (DSN) conduction study might be able to predict the neurological outcome at end of chemotherapy. Our objective was to assess its ability to early detect OXAIPN. METHODS: A total of 116 colorectal cancer patients [75 (64,6%) male, 41 (35,4%) female, median age of 64 years; range: 38-77 y.o.] were evaluated before, at middle-point and at the end of chemotherapy. Standard nerve conduction studies plus DSN were performed. The Total Neuropathy Score–clinical version (TNSc) was used to assess OXAIPN. Elaborating a tree regression, cut-offs for z-score of DSN amplitude were individuated to subdivide at mid-treatment subjects at high versus low risk to develop neurotoxicity at the end of chemotherapy. RESULTS: At baseline all patients had no preexisting neuropathy. At mid-treatment, 11 (9,5%) patients had abnormal sural nerve amplitudes and 24 (20,7%) abnormal DSN amplitudes. At the end of treatment, 37 (32%) patients had grade I neuropathy and 37 (32%) had grade II/III. Forty-four (38%) patients had abnormal sural nerve amplitudes and 55 (47,4%) had abnormal DSN amplitudes. The -0.815 cut-off for the z-score of DSN amplitude was able to individuate the probability of patients to develop OXAIPN, better than sensory nerves conventionally studied, e.g., sural nerve. CONCLUSIONS: DSN recording might be a useful objective outcome measure to individuate patients at higher risk to develop neurotoxicity during chemotherapy. It might also be a significant end-point in neuroprotection trials.
- Published
- 2014
186. Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study
- Author
-
Briani, C, Argyriou, A, Izquierdo, C, Velasco, R, Campagnolo, M, Alberti, P, Frigeni, B, Cacciavillani, M, Bergamo, F, Cortinovis, D, Cazzaniga, M, Bruna, J, Cavaletti, G, Kalofonos, H, Kalofonos, H., ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, CAVALETTI, GUIDO ANGELO, Briani, C, Argyriou, A, Izquierdo, C, Velasco, R, Campagnolo, M, Alberti, P, Frigeni, B, Cacciavillani, M, Bergamo, F, Cortinovis, D, Cazzaniga, M, Bruna, J, Cavaletti, G, Kalofonos, H, Kalofonos, H., ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, and CAVALETTI, GUIDO ANGELO
- Abstract
This prospective study sought to identify the potential reversibility of oxaliplatin-induced peripheral neuropathy (OXAIPN) by following-up its long-term course 2 years after discontinuation of oxaliplatin (OXA)-based chemotherapy. Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy. Neurological assessment, clinical Total Neuropathy Score© (TNSc©) and nerve conduction studies were performed at baseline (T0), the end of chemotherapy (T1) and 2 years (T2) after discontinuation of chemotherapy. A total of 73 of 91 (80%) patients experienced OXAIPN at T1. At a median follow-up of 25 months, persistence of chronic OXAIPN was present in 61 of 73 patients (84%) and complete resolution was present in 12 patients (17%). Longitudinal comparison of TNSc© values between T1 and T2 revealed that the overall severity of OXAIPN in those 61 patients significantly decreased over time. Median TNSc© values were nine (range: 2-15) at T1 vs. four (range: 2-12) at T2 (P < 0.001). Likewise, sensory nerve conduction measures at T2 significantly improved in all sensory nerves tested, compared with T1. Severity of OXAIPN at T2 was significantly associated (P < 0.001) with high severity of OXAIPN at T1. In conclusion, persistence of OXAIPN beyond 2 years after finishing chemotherapy is common. Clinical and neurophysiological improvement is observed, although recovery is often incomplete.
- Published
- 2014
187. Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.
- Author
-
Arpino, Grazia, primary, Truini, Mauro, additional, Montemurro, Filippo, additional, Schettini, Francesco, additional, Michelotti, Andrea, additional, Russo, Stefania, additional, Palumbo, Raffaella, additional, Cazzaniga, Marina Elena, additional, Zamagni, Claudio, additional, Lorusso, Vito, additional, Bruzzese, Dario, additional, Riccardi, Ferdinando, additional, De Laurentiis, Michelino, additional, Di Leo, Angelo, additional, Beano, Alessandra, additional, Zaniboni, Alberto, additional, Nuzzo, Antonio, additional, Malagoli, Maria, additional, Bilancia, Domenico, additional, and De Placido, Sabino, additional
- Published
- 2014
- Full Text
- View/download PDF
188. A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose
- Author
-
Alberti, P, Cortinovis, D, Cazzaniga, M, Bidoli, P, Cavaletti, G, ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, BIDOLI, PAOLO, CAVALETTI, GUIDO ANGELO, Alberti, P, Cortinovis, D, Cazzaniga, M, Bidoli, P, Cavaletti, G, ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, BIDOLI, PAOLO, and CAVALETTI, GUIDO ANGELO
- Abstract
INTRODUCTION: The real incidence of platinum drugs Chemotherapy Induced Peripheral Neuropathy (CIPN) is yet to be defined. Oxaliplatin (L-OHP) is associated with 2 different neurotoxicity: 1) acute neurotoxicity, (axonal hyperexicitability in days following iv administration with transient symptoms, such as cold-induced paresthesias); 2) chronic neuropathy, (sensory axonal one) which it is suggested to be developed in 10-20% of patients, with a threshold cumulative dose of 800-1000 mg/m2. Here an ongoing study is reported, aimed to better clarify incidence and issue in assessment, taking into account the actual L-OHP dose received by patients. METHODS: Patients eligible to undergo L-OHP based chemotherapy (FOLFOX-4) for colorectal cancer, are being enrolled. Subjects undergo a formal neurological examination, using the clinical version of the Total Neuropathy Score (TNSc), before starting CT (T0), after 6 cycles (T1) and at the end of treatment (T2); a neurophysiological assessment of limb distal nerves is also performed every time and acute toxicity phenomena record is made thorough a specifically designed questionnaire. RESULTS: Here data on 36 consecutive patients are shown. Median age was 62 (42-83); 67% of patients were male. 75% of patients were treated in an adjuvant setting. 6 patients were lost at T1 and 4 at T2, due to L-OHP discontinuation (mainly for hematological toxicities). The actual median cumulative dose was 839,5 (375,7-1021) mg/m2 and actual median dose intensity was 31,02 (14,45-42,50) mg/m2/week. At T0: median TNSc score was 0 (0-5); 17% of patients showed neurophysiological alterations. At T1: median TNSc score was 1 (0-6), 20% of patients showed alterations at neurophysiological assessment; 100% of patients showed at least one acute toxicity symptom. At T2: median score for TNSc was 4,5 (0-11), 73 % of patients showed alterations at neurophysiological assessment; 100% of patients showed at least one acute toxicity symptom. DISCUSSION: The nov
- Published
- 2012
189. When progressive dysphagia could be related to an “old friend” – a case report
- Author
-
Alberti, P, Fumagalli, L, Piatti, M, Santoro, P, Pettinaroli, R, Cortinovis, D, Cazzaniga, M, Bidoli, P, Ferrarese, C, ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, BIDOLI, PAOLO, FERRARESE, CARLO, Piatti, ML, Alberti, P, Fumagalli, L, Piatti, M, Santoro, P, Pettinaroli, R, Cortinovis, D, Cazzaniga, M, Bidoli, P, Ferrarese, C, ALBERTI, PAOLA, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, BIDOLI, PAOLO, FERRARESE, CARLO, and Piatti, ML
- Abstract
Clinical case: Here it is presented the case of a 63 years old female patient, which developed a progressive dysphagia. These are main data about her history: mastectomy (in 1997) and subsequent chemotherapy and radiotherapy for breast cancer; adrenal gland adenoma; nontoxic multinodular goiter; colon polyp (adenoma). Since 2009 she was diagnosed with an unilateral vocal cord palsy of undefined origin (neck MRI, brain MRI: negative). In December 2011 she was referred to the emergency ward due to a marked worsening of a progressive dysphagia in the last few months. She was admitted to Otorinolaringoiatric department where FBS demonstrated bilateral vocal cord hypomobility; a nasogastric sondine was placed. She was then transferred to the Neurology department where she underwent an EMG, consistent with a sensory-motor polyneuropathy; some features were also consistent with a Lambert-Eaton syndrome (Ig i.v. were started without response). She underwent a total body CT scan with contrast which was negative, apart from the yet known adrenal gland adenoma. In the mean time her clinical condition worsened: her nutritional state progressively deteriorated and her respiratory function started to become impaired with the necessity of PEG positioning and tracheostomy procedure. She then was studied with a brain MRI with mean of contrast: pathological tissue with enhancement was showed at the level of right jugular foramen, involving nerve fibers. Subsequently a biopsy was performed: histological exam revealed a localization of a breast adenocarcinoma. After completing restaging (no other sites of neoplastic disease were found), she was referred to the Oncology department were she was treated with radiotherapy (60 Gy in 30 fractions) and Letrozole. She was then discharged from the hospital in stable clinical condition; PEG and tracheostomy still placed and necessary. Conclusion: the peculiarity of this clinical case is the particular metastatic disease found, both for its being
- Published
- 2012
190. Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study.
- Author
-
Andreas, A, Alberti, P, Briani, C, Velasco, R, Bruna, J, Campagnolo, M, Cazzaniga, M, Bergamo, F, Cortinovis, D, Santos, C, Papadimitriou, K, Cavaletti, G, Kalofonos, H, ALBERTI, PAOLA, CAZZANIGA, MARINA ELENA, CORTINOVIS, DIEGO LUIGI, CAVALETTI, GUIDO ANGELO, Kalofonos, H., Andreas, A, Alberti, P, Briani, C, Velasco, R, Bruna, J, Campagnolo, M, Cazzaniga, M, Bergamo, F, Cortinovis, D, Santos, C, Papadimitriou, K, Cavaletti, G, Kalofonos, H, ALBERTI, PAOLA, CAZZANIGA, MARINA ELENA, CORTINOVIS, DIEGO LUIGI, CAVALETTI, GUIDO ANGELO, and Kalofonos, H.
- Abstract
Background: We sought to trace the incidence and severity of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to determine its clinical pattern. Among other associations, we also specifically aimed at testing whether the degree of acute neuropathy is clinically related to the development and severity of chronic OXLIPN. Methods: 170 patients (mean age 64y), scheduled to be treated with either FOLFOX or XELOX for metastatic colorectal cancer were studied. Patients were prospectively monitored at baseline and followed-up during chemotherapy in four European sites. The motor/neurosensory NCI-CTCv3 criteria and the clinical version of the Total Neuropathy Score were applied to clinically grade the severity of OXLIPN. Nerve conduction studies were also longitudinally performed. Results: Evidence of acute OXLIPN was disclosed in 146/170 patients (85.9%). The vast majority of patients manifested cold-induced perioral (95.2%) or pharyngolaryngeal dysesthesias (91.8%). Other uncommon symptoms, such as jaw spasm were also present. Severe acute OXLIPN, requiring prolongation of OXL infusion from 2 to 4-6 hours was evident in 32/146 patients (21.9%). Overall, 123/170 patients (72.4%) experienced chronic OXLIPN. Severities were grade I: 39 (22.9%); grade II: 52 (30.6%); grade III: 33 patients (19.4%). Worst severities were related to cumulative oxaliplatin dose (r:0.269;p<0.001). Follow-up assessments revealed significant decrease in all sensory action potentials examined. The severity of the acute OXLIPN was significantly correlated with both the development (r:0.450;p<0.001) and degree of the chronic form (r:0.703;p<0.001). Conclusions: Most patients treated with oxaliplatin-based chemotherapy would manifest OXLIPN, mainly of moderate degree. The severity of the acute syndrome appears to clinically correlate with the degree of the chronic form of OXLIPN. Our data suggest that acute phenomena, related to axonal hyperexcitability, could contribute to the development of peri
- Published
- 2012
191. Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment
- Author
-
Cortinovis, D, Cazzaniga, M, Cavaletti, G, Giuntini, N, Canova, S, Alberti, P, Bidoli, P, CI Perinoms Study, G, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, CAVALETTI, GUIDO ANGELO, ALBERTI, PAOLA, CI Perinoms Study Group, Cortinovis, D, Cazzaniga, M, Cavaletti, G, Giuntini, N, Canova, S, Alberti, P, Bidoli, P, CI Perinoms Study, G, CORTINOVIS, DIEGO LUIGI, CAZZANIGA, MARINA ELENA, CAVALETTI, GUIDO ANGELO, ALBERTI, PAOLA, and CI Perinoms Study Group
- Abstract
CIPN) is a dose-limiting adverse event of anticancer drugs. A simple and valid method to assess CIPN has not yet been individuated so far; lack of a gold standard measure is still an unmet clinical and scientific need, in particular mandatory to design consistent neuroprotective trials. This study was performed"to select a valid and reproducible outcome measure among existing scales. Patients and methods. These scales were selected to be tested, after a revision of literature and an expert consensus meeting: National Cancer Institute Common-Toxicity-Criteria (NCI-CTC), Total Neuropathy Score (TNSc), modified INCAT sensory sumscore (mISS), European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and CIPN20 quality of life measures. Two hundred and eighty-one cancer patients, with a proven stable CIPN and no ongoing chemotherapy, were enrolled at 20 EU/US Centers. Each patient was evaluated twice, every time by two neurologists. Inter- and intra-rater agreement was calculated through K-Cohen coefficients and 95% confidence intervals. Validity tests were performed, through Kruskal-Wallis equality-of-populations rank test, relating mISS and TNSc to NCI-CTC grades. Results. From September 2008 to December 2010, 281 patients affected by colorectal, breast, ovarian, non-small cell lung cancer and multiple myeloma were enrolled. Inter-/intra-observer scores (i.e. r >0.7) were obtained for TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were high also for EORTC QLQ-C30 and for the CIPN20. Acceptable validity scores were obtained through for mISS and TNSc compared to NCI-CTC (p values 0.04 to <0.001). Conclusions. Proper validity and reliability scores were demonstrated for selected scales. This does not imply that they are all equally reliable in CIPN assessment, since responsiveness issues have not yet been fully investigated. However presented results will help to answer this need, allowing further studies aimed to elect the gold stand
- Published
- 2012
192. PO62 DIFFERENT PATTERNS OF TREATMENT WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR TARGETED CHEMOTHERAPY IN METASTATIC BREAST CANCER: A MULTICENTER ITALIAN EXPERIENCE ON 125 WOMEN
- Author
-
Palumbo, Raffaella, primary, Cazzaniga, Marina, additional, Piazza, Elena, additional, Tondini, Carlo, additional, Ferzi, Antonella, additional, Grasso, Donatella, additional, Danova, Marco, additional, Tarenzi, Emiliana, additional, Sottotetti, Federico, additional, Villa, Federica, additional, Gambaro, Anna, additional, Caremoli, Elena Rota, additional, Collovà, Elena, additional, Cavalli, Carla, additional, and Bernardo, Antonio, additional
- Published
- 2013
- Full Text
- View/download PDF
193. Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis.
- Author
-
Coltelli, Luigi, primary, Fontana, Andrea, additional, Bocci, Guido, additional, Camerini, Andrea, additional, Ferro, Antonella, additional, Cazzaniga, Marina Elena, additional, Casadei, Virginia, additional, Pazzagli, Ilaria, additional, Marcucci, Lorenzo, additional, Allegrini, Giacomo, additional, Lucchesi, Sara, additional, Bona, Eleonora, additional, Scalese, Marco, additional, Orlandi, Paola, additional, Villa, Federica, additional, Morini, Silvano, additional, Amoroso, Domenico, additional, Arrighi, Giada, additional, Filidei, Mario, additional, and Falcone, Alfredo, additional
- Published
- 2013
- Full Text
- View/download PDF
194. Clinical pattern and associations of oxaliplatin acute neurotoxicity
- Author
-
Argyriou, Andreas A., primary, Cavaletti, Guido, additional, Briani, Chiara, additional, Velasco, Roser, additional, Bruna, Jordi, additional, Campagnolo, Marta, additional, Alberti, Paola, additional, Bergamo, Francesca, additional, Cortinovis, Diego, additional, Cazzaniga, Marina, additional, Santos, Cristina, additional, Papadimitriou, Konstantinos, additional, and Kalofonos, Haralabos P., additional
- Published
- 2012
- Full Text
- View/download PDF
195. Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study.
- Author
-
Argyriou, Andreas, primary, Alberti, Paola, additional, Briani, Chiara, additional, Velasco, Roser, additional, Bruna, Jordi, additional, Campagnolo, Marta, additional, Cazzaniga, Marina Elena, additional, Bergamo, Francesca, additional, Cortinovis, Diego Luigi, additional, Santos, Cristina, additional, Papadimitriou, Konstantinos, additional, Cavaletti, Guido, additional, and Kalofonos, Haralabos, additional
- Published
- 2012
- Full Text
- View/download PDF
196. Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era
- Author
-
Petrelli, Fausto, primary, Cabiddu, Mary, additional, Cazzaniga, Marina Elena, additional, Cremonesi, Marco, additional, and Barni, Sandro, additional
- Published
- 2008
- Full Text
- View/download PDF
197. Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations.
- Author
-
Del Mastro, Lucia, Cazzaniga, Marina, Solidoro, Paolo, Generali, Daniele, Bianchi, Giulia, Testore, Franco, and De Placido, Sabino
- Published
- 2015
- Full Text
- View/download PDF
198. Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study
- Author
-
Cazzaniga, Marina E., primary, Dogliotti, Luigi, additional, Cascinu, Stefano, additional, Barni, Sandro, additional, Labianca, Roberto, additional, Chiara, Silvana, additional, Conte, Pier Franco, additional, Gasparini, Giampietro, additional, Pasetto, Lara, additional, and Torri, Valter, additional
- Published
- 2006
- Full Text
- View/download PDF
199. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
- Author
-
Allegrini, Giacomo, Coltelli, Luigi, Orlandi, Paola, Fontana, Andrea, Camerini, Andrea, Ferro, Antonella, Cazzaniga, Marina, Casadei, Virginia, Lucchesi, Sara, Bona, Eleonora, Di Lieto, Marco, Pazzagli, Ilaria, Villa, Federica, Amoroso, Domenico, Scalese, Marco, Arrighi, Giada, Molinaro, Sabrina, Fioravanti, Anna, Finale, Chiara, and Triolo, Renza
- Abstract
Aim: To investigate pharmacogenetic interactions among VEGF-A, VEGFR-2, IL-8, HIF-1α, EPAS-1 and TSP-1 SNPs and their role on progression-free survival in a population of metastatic breast cancer patients treated with bevacizumab in combination with first-line paclitaxel. Patients & methods: Analyses were performed on germline DNA obtained from blood samples and SNPs were investigated by real-time polymerase chain reaction technique. The multifactor dimensionality reduction methodology was applied to investigate the interaction between SNPs. Results: One hundred and thirteen patients were enrolled from eight Italian Oncology Units (: NCT01935102). The multifactor dimensionality reduction software provided two pharmacogenetic interaction profiles consisting of the combination between specific VEGFR-2 rs11133360 and IL-8 rs4073 genotypes. The median progression-free survival was 14.1 months (95% CI: 11.4-16.8) and 10.2 months (95% CI: 8.8-11.5) for the favorable and the unfavorable genetic profile, respectively (HR: 0.44, 95% CI: 0.29-0.66, p < 0.0001). Conclusion: The pharmacogenetic statistical interaction between VEGFR-2 rs11133360 and IL-8 rs4073 genotypes may identify a population of patients with a better outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
200. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
- Author
-
Briani, Chiara, Argyriou, Andreas A., Izquierdo, Cristina, Velasco, Roser, Campagnolo, Marta, Alberti, Paola, Frigeni, Barbara, Cacciavillani, Mario, Bergamo, Francesca, Cortinovis, Diego, Cazzaniga, Marina, Bruna, Jordi, Cavaletti, Guido, and Kalofonos, Haralabos P.
- Subjects
TREATMENT of peripheral neuropathy ,CANCER treatment ,NEUROTOXICOLOGY ,ANTINEOPLASTIC combined chemotherapy protocols ,CANCER chemotherapy ,CHI-squared test ,LONGITUDINAL method ,EVALUATION of medical care ,MEDICAL cooperation ,POLYNEUROPATHIES ,RESEARCH ,RESEARCH funding ,STATISTICS ,T-test (Statistics) ,TUMORS ,DATA analysis ,OXALIPLATIN ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
This prospective study sought to identify the potential reversibility of oxaliplatin-induced peripheral neuropathy ( OXAIPN) by following-up its long-term course 2 years after discontinuation of oxaliplatin ( OXA)-based chemotherapy. Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy. Neurological assessment, clinical Total Neuropathy Score© ( TNSc©) and nerve conduction studies were performed at baseline ( T0), the end of chemotherapy ( T1) and 2 years ( T2) after discontinuation of chemotherapy. A total of 73 of 91 (80%) patients experienced OXAIPN at T1. At a median follow-up of 25 months, persistence of chronic OXAIPN was present in 61 of 73 patients (84%) and complete resolution was present in 12 patients (17%). Longitudinal comparison of TNSc© values between T1 and T2 revealed that the overall severity of OXAIPN in those 61 patients significantly decreased over time. Median TNSc© values were nine (range: 2-15) at T1 vs. four (range: 2-12) at T2 (P < 0.001). Likewise, sensory nerve conduction measures at T2 significantly improved in all sensory nerves tested, compared with T1. Severity of OXAIPN at T2 was significantly associated (P < 0.001) with high severity of OXAIPN at T1. In conclusion, persistence of OXAIPN beyond 2 years after finishing chemotherapy is common. Clinical and neurophysiological improvement is observed, although recovery is often incomplete. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.